title: Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.
abstract: The effects of diet, of non-steroidal anti-inflammatory drugs, or of their combination on carcinogenesis continue to be a case for controversy. Diets that are high in fat have been linked to increased risk of various tumors. At the same time there is substantial, but not conclusive, evidence that the risk of breast and colon cancer correlates with total fat intake rather than a specific type of fat. On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs) have been studied extensively because they appear to delay or inhibit the development of malignant and pre-malignant lesions. 7,12-Dimethylbenz-(a)-anthracene (DMBA) has been used for a long time to induce carcinogenesis in a number of rat animal models. The present study attempts to identify the effects on DMBA-induced tumor growth (a) of diets rich in fat and (b) of the highly selective COX-2 inhibitor Celecoxib, which has been claimed to offer substantial protection against carcinogenesis.
authors.affiliation: 1st Surgical Department, Papageorgiou Hospital, Faculty of Medicine, University of Thessaloniki.
authors.forename: S
authors.initials: S
authors.lastname: Miliaras
authors.forename: A
authors.initials: A
authors.lastname: Anogeianaki
authors.forename: S
authors.initials: S
authors.lastname: Meditskou
authors.forename: V
authors.initials: V
authors.lastname: Kefala
authors.forename: D
authors.initials: D
authors.lastname: Koutsonikolas
authors.forename: J
authors.initials: J
authors.lastname: Liangouris
authors.forename: G
authors.initials: G
authors.lastname: Anogianakis
authors.forename: D
authors.initials: D
authors.lastname: Miliaras
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000230:Adenocarcinoma / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D031204:Caloric Restriction; D000068579:Celecoxib; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000187:drug effects / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004041:Dietary Fats / Q000633:toxicity*; D005260:Female; D015674:Mammary Neoplasms, Animal / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control; D009369:Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012509:Sarcoma / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D004041:Dietary Fats; D011720:Pyrazoles; D013449:Sulfonamides; D015127:9,10-Dimethyl-1,2-benzanthracene; D051546:Cyclooxygenase 2; C489691:Ptgs2 protein, rat; D000068579:Celecoxib